Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/12/2017 10/13/2017 10/16/2017 10/17/2017 10/18/2017 Date
65.35(c) 65.29(c) 63.65(c) 64.18(c) 63.7(c) Last
5 339 734 6 209 580 6 692 649 5 030 781 5 595 032 Volume
+0.37% -0.09% -2.51% +0.83% -0.75% Change
More quotes
Financials ($)
Sales 2017 20 531 M
EBIT 2017 5 540 M
Net income 2017 4 544 M
Finance 2017 288 M
Yield 2017 2,46%
Sales 2018 21 127 M
EBIT 2018 5 763 M
Net income 2018 4 900 M
Finance 2018 1 958 M
Yield 2018 2,55%
P/E ratio 2017 23,33
P/E ratio 2018 21,01
EV / Sales2017 5,11x
EV / Sales2018 4,89x
Capitalization 105 B
More Financials
Company
Bristol-Myers Squibb Co. operates as a biopharmaceutical company, which engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products.It includes chemically-synthesized drugs or small molecules and products produced from biological... 
Sector
Pharmaceuticals
Calendar
10/18 | 01:30amPresentation
More about the company
Surperformance© ratings of Bristol-Myers Squibb Compa
Trading Rating : Investor Rating :
More Ratings
Latest news on BRISTOL-MYERS SQUIBB COMPA
09:08a JOHNSON & JOHNSON : Missouri appeals court throws out $72 million award in Johns..
10/17 BRISTOL MYERS SQUIBB : Hundreds of patients to have access to head and neck canc..
10/16 BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration (FDA) Accepts Bristol-M..
10/16 TARGET PHARMASOLUTIONS, BRISTOL-MYER : BMY) Extend Partnership
10/16 BRISTOL-MYERS SQUIBB COMPANY : Corporate News Blog - Bristol-Myers Squibb's Opdi..
10/16 BRISTOL MYERS SQUIBB : Opdivo Alone or Combined with Yervoy Shows Encouraging Re..
10/12 EXELIXIS : to Receive Milestone Payment from Bristol-Myers Squibb for Submission..
10/12 BRISTOL MYERS SQUIBB : Trademark Application for "FRIXT" Filed
10/12 BRISTOL MYERS SQUIBB : An Application for the Trademark "ZUSVIVLI" Has Been File..
10/12 BRISTOL MYERS SQUIBB : Trademark Application for "JATURBI" Filed by Bristol-Myer..
More news
Sector news : Pharmaceuticals - NEC
12:43p FTSE rises to record close, blue-chips shrug off Reckitt blip
10:43a ALLERGAN : ruling casts doubt on tribal patent strategy
09:09aDJELI LILLY AND : Lilly To Develop Cancer Vaccine Products with CureVac -- Market ..
02:52aDJASTRAZENECA : Breast-Cancer Drug Gets Priority Review From FDA
02:48aDJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on BRISTOL-MYERS SQUIBB COMPA 
BRISTOL-MYERS SQUIBB CO - 2016
Attractive price levels
BUY
More Strategies
Latest Tweets
05:50p@ SMIpharm: RT PharmaMKTnet: Examine how Bristol Myers Squibb create an digit.. 
05:40p$BMY wants Opdivo used earlier in cancer, and a new melanoma approval could b.. 
04:27pDowngrades in past wk: $BMY (Jeffries) $F (RBC) $ULTA (Goldman, Piper) $MGM ..
5
03:30pWed's Top Analyst Up & Downgrades PT2 $AAN $ATH $BECN $BMY $EQIX $GNRC $H.. 
03:22pWednesday's Top Analyst Upgrades and Downgrades PT2 $AAN $ATH $BECN $BMY $EQ.. 
More tweets
Qtime:172
News from SeekingAlpha
09:00a 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 18, 2017
08:58a Exploring AstraZeneca's Two-Prong Assault On Lung Cancer
10/17 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 17, 2017
10/17 BIOTECH ANALYSIS CENTRAL : Daily Pharma News - October 17, 2017
10/16 Merck's Risk/Reward Is Compelling
Chart BRISTOL-MYERS SQUIBB COMPA
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 23
Average target price 59,8 $
Spread / Average Target -6,8%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY11.72%105 250
JOHNSON & JOHNSON18.42%377 880
NOVARTIS13.23%225 650
ROCHE HOLDING LTD.5.20%217 022
PFIZER11.88%215 576
MERCK AND COMPANY7.68%172 423